Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression

Thrombosis Research

Volumn 100, Issue 6, 2000, Pages 479-488

  Scazziota, Alejandra ^a   Altman, Raul ^a   Rouvier, Jorge ^a   Gonzalez, Claudio ^a   Ahmed, Zulfiqar ^b   Jeske, Walter P ^b   Walenga, Jeanine M ^b   Fareed, Jawed ^b  

^a Centro de Trombosis de Buenos Aires   (Argentina)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abciximab; Aspirin; Coronary disease; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CYCLOOXYGENASE 1 INHIBITOR; INDOMETACIN; PADGEM PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STATISTICAL ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADULT; ANTIBODIES, MONOCLONAL; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 0034671902     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00361-3     Document Type: Article

References (22)

1. Aspirin as an antiplatelet drug
2. Aspirin, platelets, and thrombosis: Theory and practice
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
4. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial
5. Meeting highlights
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with coronary syndromes
7. Synergistic activity of Paf-acether and sodium arachidonate in human platelet aggregation: II. Unexpected results after aspirin intake
8. Why single daily dose of aspirin may not prevent platelet aggregation
9. European working group on clinical cell analysis: Consensus protocol for the flow cytometric characterization of platelet function
10. Platelet, endothelial cells, and the thrombotic process
11. Inhibition of platelet glycoprotein IIb/IIIa receptors: Will they be useful when given chronically?
12. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia
13. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries
14. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increasing thromboxane production, adenosine diphosphate release, and recruitment
15. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin
16. Why aspirin cannot prevent arterial thrombosis
17. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
18. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
19. Concept and clinical application of platelet glycoprotein IIb/IIIa inhibition with abciximab (c7E3 Fab; ReoPro) for the prevention of acute ischemic syndromes
20. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors
21. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in myocardial infarction
22. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa in patients undergoing coronary angioplasty